Sartorius AG

1SRT

Company Profile

  • Business description

    Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs and focuses on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.

  • Contact

    Otto-Brenner-Strasse 20
    GottingenNI37079
    DEU

    T: +49 5513080

    E: [email protected]

    https://www.sartorius.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Medical Instruments & Supplies

    Fiscal Year End

    31 December 2026

    Employees

    14,242

Stocks News & Analysis

stocks

ASX tech share tracking below guidance

Moat Rating downgraded for overvalued shares.
stocks

After plunge ASX blue chip undervalued

This company earns a moat from our analysts.
stocks

Older cohorts the budget losers, not necessarily the ASX listed insurers

Proposed legislation removes health insurance rebates.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,717.0082.40-0.94%
CAC 408,117.42135.661.70%
DAX 4024,737.24336.591.38%
Dow JONES (US)49,955.74591.861.20%
FTSE 10010,432.34101.790.99%
HKSE25,651.12146.73-0.57%
NASDAQ26,202.77332.061.28%
Nikkei 22559,804.41746.18-1.23%
NZX 50 Index12,761.03213.29-1.64%
S&P 5007,420.3166.700.91%
S&P/ASX 2008,496.6076.50-0.89%
SSE Composite Index4,162.187.35-0.18%

Market Movers